Healthcare Outlook

Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy.

Request a Sample of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2609

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers

Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in clinical trials. Furthermore, in March 2018, CSL Behring received U.S. FDA approval for Hizentra, which is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient treatment type, in which patients can infuse themselves. The approval was based on the phase III results of the clinical trial. These factors are expected to propel the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other organizations are expected to have an influence on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome & Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Key Players

Some of the major players operating in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market include CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc., GeNeuro SA ,Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd. and Nihon Pharmaceutical Co. Ltd.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment Market Taxonomy

The global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market is segmented by treatment type, distribution channel and regions.

By Treatment Type

- Intravenous immunoglobulin therapy

Privigen

Hizentra

Gamunex-C

Tegeline

Others

- Corticosteroids

- Others

By Distribution Channel

Hospital pharmacies

Retail pharmacies

Online pharmacies

Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/chronic-inflammatory-demyelinating-polyneuropathy-cidp-treatment-market-2609

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com